BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
- PMID: 10589777
BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
Abstract
Matrix metalloproteinases (MMPs) have been implicated in tumor cell invasion, metastasis, and angiogenesis. BAY 12-9566, a novel, non-peptidic biphenyl MMP inhibitor, has shown preclinical activity on a broad range of tumor models and is currently in clinical development. The purpose of this study was to investigate the antiangiogenic activity of BAY 12-9566. In vitro, BAY 12-9566 prevented matrix invasion by endothelial cells in a concentration-dependent manner (IC50 = 8.4x10(-7) M), without affecting cell proliferation. In vivo, oral daily administration of BAY 12-9566 (50-200 mg/kg) inhibited angiogenesis induced by basic fibroblast growth factor in the Matrigel plug assay, reducing the hemoglobin content of the pellets. Histological analysis showed a reduction in the amount of functional vessels within the Matrigel. We conclude that the MMP inhibitor BAY 12-9566 inhibits angiogenesis, a property that further supports its clinical development as an antimetastatic agent.
Similar articles
-
Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model.Clin Exp Metastasis. 2003;20(5):407-12. doi: 10.1023/a:1025473709656. Clin Exp Metastasis. 2003. PMID: 14524529
-
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.Cancer Res. 2001 Dec 1;61(23):8480-5. Cancer Res. 2001. PMID: 11731431
-
Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.Mol Cancer Ther. 2002 Nov;1(13):1191-200. Mol Cancer Ther. 2002. PMID: 12479700
-
Antiangiogenic property of human thrombin.Microvasc Res. 2003 Jul;66(1):1-14. doi: 10.1016/s0026-2862(03)00037-2. Microvasc Res. 2003. PMID: 12826069 Review.
-
Development of matrix metalloproteinase inhibitors in cancer therapy.J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. doi: 10.1093/jnci/93.3.178. J Natl Cancer Inst. 2001. PMID: 11158186 Review.
Cited by
-
Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
-
Short term effect of tetrahydrocurcumin on adipose angiogenesis in very high-fat diet-induced obesity mouse model.Front Nutr. 2023 Oct 9;10:1221935. doi: 10.3389/fnut.2023.1221935. eCollection 2023. Front Nutr. 2023. PMID: 37876615 Free PMC article.
-
Metal Complexes as Promising Matrix Metalloproteinases Regulators.Int J Mol Sci. 2023 Jan 9;24(2):1258. doi: 10.3390/ijms24021258. Int J Mol Sci. 2023. PMID: 36674771 Free PMC article. Review.
-
Proteolytic cleavage of membrane proteins by membrane type-1 MMP regulates cancer malignant progression.Cancer Sci. 2023 Feb;114(2):348-356. doi: 10.1111/cas.15638. Epub 2022 Nov 24. Cancer Sci. 2023. PMID: 36336966 Free PMC article. Review.
-
The Role of Matrix Metalloproteinases in Endometriosis: A Potential Target.Biomolecules. 2021 Nov 22;11(11):1739. doi: 10.3390/biom11111739. Biomolecules. 2021. PMID: 34827737 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources